Live
- Purandeswari responds to Allu Arjun arrest in stampede case, says it is not one's fault
- Threads of trust and love
- Belagavi AICC session centenary message
- Gold rates in Hyderabad today stable, check the rates on 22 December, 2024
- Radiant High School should be de-recognized: Student associations
- Int’l conference on ‘Pearls in Clinical Neurology’ held
- Parliament tussle puts every Indian to shame
- Learning to navigate life’s storms
- Gold rates in Visakhapatnam today stable, check the rates on 22 December, 2024
- South Korea holds largest share of US battery material import market
Dr Reddy's signs strategic deal with Gland Pharma
City-based Dr Reddy\'s Laboratories Ltd on Wednesday said that it had entered into a strategic collaboration with Gland Pharma, a globally recognized developer and manufacturer of sterile dosage forms, to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs) in the US market.
Hyderabad: City-based Dr Reddy's Laboratories Ltd on Wednesday said that it had entered into a strategic collaboration with Gland Pharma, a globally recognized developer and manufacturer of sterile dosage forms, to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs) in the US market.
The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the US. The combined sale of branded and generic versions of the products in the US is nearly $1 billion for the most recent 12 months ending August 2016, according to IMS Health.
"Dr Reddy's Laboratories has a strong track record in developing, marketing and distributing generic injectables in the US. Our strengths, combined with Gland's track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our specialty injectables offering in the short-to-medium term," said Alok Sonig, Executive Vice President and Head of North America, Dr Reddy's. Srinivas Sadu, Chief Operating Officer, Gland Pharma, hoped that the company’s partnership with Dr Reddy's would continue to grow.
